Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis
Background The effects of omega-3 fatty acids (FAs), such as eicosapentaenoic (EPA) and
docosahexaenoic (DHA) acids, on cardiovascular outcomes are uncertain. We aimed to …
docosahexaenoic (DHA) acids, on cardiovascular outcomes are uncertain. We aimed to …
International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia
This contemporary, international, evidence-informed guidance aims to achieve the greatest
good for the greatest number of people with familial hypercholesterolaemia (FH) across …
good for the greatest number of people with familial hypercholesterolaemia (FH) across …
2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American …
SS Virani, PB Morris, A Agarwala… - Journal of the American …, 2021 - jacc.org
The American College of Cardiology (ACC) has a long history of developing documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …
decision pathways, health policy statements, appropriate use criteria) to provide members …
Effects of n-3 fatty acid supplements in elderly patients after myocardial infarction: a randomized, controlled trial
AA Kalstad, PL Myhre, K Laake, SH Tveit, EB Schmidt… - Circulation, 2021 - Am Heart Assoc
Background: High intake of marine n-3 polyunsaturated fatty acids (PUFA) has been
associated with reduced risk of cardiovascular events; however, this has not been confirmed …
associated with reduced risk of cardiovascular events; however, this has not been confirmed …
Role of omega-3 fatty acids in cardiovascular disease: the debate continues
Abstract Purpose of Review The omega-3 fatty acids (n3-FAs), eicosapentaenoic acid (EPA)
and docosahexaenoic acid (DHA), have recently undergone testing for their ability to reduce …
and docosahexaenoic acid (DHA), have recently undergone testing for their ability to reduce …
Association of lipoprotein (a) with atherosclerotic plaque progression
Abstract Background Lipoprotein (a)[Lp (a)] is associated with increased risk of myocardial
infarction, although the mechanism for this observation remains uncertain. Objectives This …
infarction, although the mechanism for this observation remains uncertain. Objectives This …
Coronary Atherosclerotic Plaque Regression: JACC State-of-the-Art Review
LP Dawson, M Lum, N Nerleker, SJ Nicholls… - Journal of the American …, 2022 - jacc.org
Over the last 3 decades there have been substantial improvements in treatments aimed at
reducing cardiovascular (CV) events. As these treatments have been developed, there have …
reducing cardiovascular (CV) events. As these treatments have been developed, there have …
Practical guidance for combination lipid-modifying therapy in high-and very-high-risk patients: a statement from a European Atherosclerosis Society Task Force
Abstract Background and aims This European Atherosclerosis Society (EAS) Task Force
provides practical guidance for combination therapy for elevated low-density lipoprotein …
provides practical guidance for combination therapy for elevated low-density lipoprotein …
Novel and future lipid-modulating therapies for the prevention of cardiovascular disease
J Brandts, KK Ray - Nature Reviews Cardiology, 2023 - nature.com
Lowering the levels of LDL cholesterol in the plasma has been shown to reduce the risk of
atherosclerotic cardiovascular disease (ASCVD). Several other lipoproteins, such as …
atherosclerotic cardiovascular disease (ASCVD). Several other lipoproteins, such as …
Coronary heart disease risk: low-density lipoprotein and beyond
Coronary heart disease (CHD) is the leading cause of morbidity and mortality world-wide
and has been characterized as a chronic immunoinflammatory, fibroproliferative disease …
and has been characterized as a chronic immunoinflammatory, fibroproliferative disease …